Fresenius expands Biopharma Portfolio in the U.S. with Denosumab Biosimilars availability

Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence ®(1) (denosumab-bnht) and Bomyntra ®(2) (denosumab-bnht). These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia ®(3) (denosumab) and Xgeva ®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions. This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius. Conexxence ®(1) and Bomyntra ®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia ®(3) and Xgeva ®(4) are registered trademarks of Amgen Inc. Read the full press release here . FOLLOW US Fans Follower Follower THE HEALTHCARE GROUP Fresenius-Websites Group Overview CONTACT US Fresenius SE & Co. KGaA Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany T +49 (0) 6172 608-0 Contacts Our Grievance Mechanism VISIT US How to get here (PDF, 2242,72kb) Worldwide Fresenius SE & Co. KGaA Imprint | Data Protection | Legal Disclaimer

The release as fetched from its publisher. fresenius.com ↗